Amarin Claims ‘Little Impact’ From Teva’s US Vascepa Generic
Originator Aware Of Potential Fifth Launch From Zydus Cadila
Executive Summary
“They have prescriptions just in the hundreds per week, which is in a market of 100,000 or so prescriptions a week,” Amarin has said of Teva’s Vascepa generic, the fourth to reach the US market.